AWH लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 21:39):

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States...

Stats
आज की मात्रा	8 416.00
औसत मात्रा	22 613.00
बाजार मूल्य	35.37M
EPS	$0 ( 2024-03-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.580
ATR14	$0.0520 (1.78%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-03	Milligan Sandra	Buy	30 000	EMPLOYEE STOCK OPTION (RIGHT TO BUY)
2024-04-01	Milligan Sandra	Buy	0
2024-02-15	Sandford Nicole	Buy	30 000	Employee stock option (right to buy)
2024-02-14	Hombeck Torsten	Buy	20 000	Employee stock option (right to buy)
2024-02-14	Merchant Minh Hoang	Buy	11 000	Employee stock option (right to buy)

INSIDER POWER
97.47
Last 89 transactions
Buy: 4 309 531 \| Sell: 195 424

Aspira Women's Health सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Aspira Women's Health वित्तीय

Annual	2023
राजस्व:	$9.15M
सकल लाभ:	$5.26M (57.48 %)
EPS:	$-1.810

FY	2023
राजस्व:	$9.15M
सकल लाभ:	$5.26M (57.48 %)
EPS:	$-1.810

FY	2022
राजस्व:	$8.18M
सकल लाभ:	$4.32M (52.77 %)
EPS:	$-41.66

FY	2021
राजस्व:	$6.81M
सकल लाभ:	$3.06M (44.95 %)
EPS:	$-0.280

Financial Reports:

No articles found.

Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

के लिए वास्तविक समय के अद्यतन Aspira Women's Health [AWH]

Upcoming Earnings Alert